久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂博生物技術(shù)有限公司
   
     
聯(lián)系熱線
  • 聯(lián)系人:方經(jīng)理
  • 電 話:027-65279366
  • 郵箱:products@biolabreagent.com
  • 地 址:武漢市東湖新技術(shù)開發(fā)區(qū)神墩四路666號C棟

佰樂博生物代理AntibodySystem,InVivoMAb Anti-Rat CD198/CCR8 Antibody (Iv0256)體內(nèi)中和抗體,活性抗體

發(fā)表時間:2024-05-30

佰樂博生物代理AntibodySystem,InVivoMAb Anti-Rat CD198/CCR8 Antibody (Iv0256)體內(nèi)中和抗體,活性抗體

鏈接:https://www.antibodysystem.com/product/21632.html

名稱:InVivoMAb Anti-Rat CD198/CCR8 Antibody (Iv0256)體內(nèi)中和抗體,活性抗體

別名:C-C motif chemokine receptor 8, Ccr8

貨號:VRE85601

宿主:Mouse

適用物種:Rat

存儲緩沖區(qū):0.01M PBS, pH 7.4.

形式:Liquid

純度:>95%

克?。?/span>Monoclonal

同型:IgG2a, kappa

應(yīng)用:ELISA, Neutralization

內(nèi)毒素水平Please contact with the lab for this information.

UniProtD4ADE0

用途范圍:僅用于科研

儲存:Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

產(chǎn)品購買聯(lián)系方式:027-65279366 /18162686757

郵箱:biolab-reagents@atagenix.com

QQ:2663991332

 

參考文獻:

CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. PMID: 35140181

Chemokine Receptor-Targeted Therapies: Special Case for CCR8. PMID: 35158783

Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. PMID: 36352891

S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells. PMID: 37420296

Blocking CCL8-CCR8-Mediated Early Allograft Inflammation Improves Kidney Transplant Function. PMID: 35973731

CD4(+)CCR8(+) Tregs in ovarian cancer: a potential effector Tregs for immune regulation. PMID: 37950246

Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation. PMID: 37770937

The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer. PMID: 35354899

TGF-beta-induced CCR8 promoted macrophage transdifferentiation into myofibroblast-like cells. PMID: 35377281

CCR8 is a new therapeutic target in cutaneous T-cell lymphomas. PMID: 35201316

Immunotherapy Targeting CCR8+ Regulatory T Cells Induces Antitumor Effects via Dramatic Changes to the Intratumor CD8+ T Cell Profile. PMID: 37350632

Cutting Edge: CCR8 Signaling Regulates IL-25- and IL-33-Responsive Skin Group 2 Innate Lymphoid Cell Migration and Function. PMID: 37921466

C(8)Mab-3: An Anti-Mouse CCR8 Monoclonal Antibody for Immunocytochemistry. PMID: 35377236

CCR8 Signaling via CCL1 Regulates Responses of Intestinal IFN-gamma Producing Innate Lymphoid CelIs and Protects From Experimental Colitis. PMID: 33613532

CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer. PMID: 32367308

Role of chemokines in the crosstalk between tumor and tumor-associated macrophages. PMID: 36173487

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies. PMID: 35693763

聯(lián)系方式
手機:18162686757
微信掃一掃
桑植县| 开江县| 全州县| 黄冈市| 潜江市| 康乐县| 廉江市| 阿拉尔市| 金平| 墨竹工卡县| 昔阳县| 南昌县| 张掖市| 贺兰县| 九寨沟县| 游戏| 甘泉县| 昆山市| 桃园县| 连云港市| 鄂伦春自治旗| 贵南县| 长泰县| 昌图县| 灵丘县| 永年县| 印江| 菏泽市| 吕梁市| 城市| 巴林左旗| 洪洞县| 浦北县| 靖远县| 吉安县| 临邑县| 永康市| 临西县| 丹寨县| 南乐县| 墨江|